Many Australian HER2+ metastatic breast cancer (MBC) patients with bone metastases do not receive a bone modifying agent (BMA) and there is significant practice variation among clinicians when it comes to dosing, interval schedules and de-escalating the therapy, registry data shows. The prospective review of patient data from the HER2+ MBC registry, TABITHA, is the ...
Spotlight on oncologist use of bone modifying agents
By Sunalie Silva
21 May 2021